{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:12:49Z","timestamp":1772165569811,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T00:00:00Z","timestamp":1576713600000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Anesthesiol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Perioperative immune function plays an important role in the prognosis of patients. Several studies have indicated that low-dose opioid receptor blockers can improve immune function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Sixty-nine patients undergoing video-assisted thoracoscopic resection of the lung cancer were randomly assigned to either the naloxone group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200935) or the non-naloxone group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200934) for postoperative analgesia during the first 48\u2009h after the operation. Both groups received sufentanil and palonosetron via postoperative analgesia pump, while 0.05\u2009\u03bcg\u00b7kg\n                      <jats:sup>\u2212\u20091<\/jats:sup>\n                      \u00b7h\n                      <jats:sup>\u2212\u20091<\/jats:sup>\n                      naloxone was added in naloxone group. The primary outcomes were the level of opioid growth factor (OGF) and immune function assessed by natural killer cells and CD4\n                      <jats:sup>+<\/jats:sup>\n                      \/CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell ratio. Second outcomes were assessed by the intensity of postoperative pain, postoperative rescue analgesia dose, postoperative nausea and vomiting (PONV).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The level of OGF in the naloxone group increased significantly at 24\u2009h (\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001) and 48\u2009h after the operation (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01). The natural killer cells (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05) and CD4\n                      <jats:sup>+<\/jats:sup>\n                      \/CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell ratio (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01) in the naloxone group increased significantly at 48\u2009h after the operation. The rest VAS scores were better with naloxone at 12 and 24\u2009h after operation(\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05), and the coughing VAS scores were better with naloxone at 48\u2009h after the operation(\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). The consumption of postoperative rescue analgesics in the naloxone group was lower (0.00(0.00\u20130.00) vs 25.00(0.00\u201362.50)),\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). Postoperative nausea scores at 24\u2009h after operation decreased in naloxone group(0.00 (0.00\u20130.00) vs 1.00 (0.00\u20132.00),\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Infusion of 0.05\u2009\u03bcg\u00b7kg\n                      <jats:sup>\u2212\u20091<\/jats:sup>\n                      \u00b7h\n                      <jats:sup>\u2212\u20091<\/jats:sup>\n                      naloxone for patients undergoing sufentanil-controlled analgesia for postoperative pain can significantly increase the level of OGF, natural killer cells, and CD4+\/CD8+ T-cell ratio compared with non-naloxone group, and postoperative pain intensity, request for rescue analgesics, and opioid-related side effects can also be reduced.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      The trial was registered at the Chinese Clinical Trial Registry on January 26, 2019 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\">ChiCTR1900021043<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12871-019-0912-6","type":"journal-article","created":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T09:02:39Z","timestamp":1576746159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effect of low dose naloxone on the immune system function of a patient undergoing video-assisted thoracoscopic resection of lung cancer with sufentanil controlled analgesia \u2014 a randomized controlled trial"],"prefix":"10.1186","volume":"19","author":[{"given":"Yun","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuang","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang-fang","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4172-9813","authenticated-orcid":false,"given":"Qing-ping","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,19]]},"reference":[{"issue":"1","key":"912_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/ijc.31664","volume":"144","author":"S Pilleron","year":"2019","unstructured":"Pilleron S, Sarfati D, Janssen-Heijnen M, Vignat J, Ferlay J, Bray F, Soerjomataram I. Global cancer incidence in older adults, 2012 and 2035: a population-based study. Int J Cancer. 2019;144(1):49\u201358.","journal-title":"Int J Cancer"},{"issue":"6","key":"912_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"912_CR3","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/S1470-2045(15)00223-5","volume":"16","author":"R Sullivan","year":"2015","unstructured":"Sullivan R, Alatise OI, Anderson BO, Audisio R, Autier P, Aggarwal A, et al. Global cancer surgery: delivering safe, affordable, and timely cancer surgery. Lancet Oncol. 2015;16(11):1193\u2013224.","journal-title":"Lancet Oncol"},{"issue":"2","key":"912_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/bja\/aeq164","volume":"105","author":"GL Snyder","year":"2010","unstructured":"Snyder GL, Greenberg S. Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth. 2010;105(2):106\u201315.","journal-title":"Br J Anaesth"},{"issue":"4","key":"912_CR5","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1097\/ALN.0b013e318210f880","volume":"114","author":"NJ Stagg","year":"2011","unstructured":"Stagg NJ, Mata HP, Ibrahim MM, Henriksen EJ, Porreca F, Vanderah TW, Malan TP. Regular exercise reverses sensory hypersensitivity in a rat neuropathic pain modelrole of endogenous opioids. Anesthesiology. 2011;114(4):940\u20138.","journal-title":"Anesthesiology"},{"issue":"3","key":"912_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0165-0173(01)00160-6","volume":"38","author":"IS Zagon","year":"2002","unstructured":"Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Rev. 2002;38(3):351\u201376.","journal-title":"Brain Res Rev"},{"issue":"1","key":"912_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0014-2999(98)00079-X","volume":"347","author":"J Kowalski","year":"1998","unstructured":"Kowalski J. Immunologic action of [Met5] enkephalin fragments. Eur J Pharmacol. 1998;347(1):95\u20139.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"912_CR8","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/j.1749-6632.1987.tb35821.x","volume":"496","author":"NP Plotnikoff","year":"1987","unstructured":"Plotnikoff NP, Miller GC, Nimeh N, Faith RE, Murgo AJ, Wybran J. Enkephalins and T-cell enhancement in Normal volunteers and Cancer patients. Ann N Y Acad Sci. 1987;496(1):608\u201319.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"912_CR9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1749-6632.1987.tb35753.x","volume":"496","author":"J Wybran","year":"1987","unstructured":"Wybran J, Schanden\u00e9 L, Van Vooren JP, Vandermoten G, Latinne D, Sonnet J, et al. Immunologic properties of methionine-Enkephalin, and therapeutic implications in AIDS, ARC, and Cancer. Ann N Y Acad Sci. 1987;496(1):108\u201314.","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"912_CR10","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1097\/00000542-199711000-00011","volume":"87","author":"TJ Gan","year":"1997","unstructured":"Gan TJ, Ginsberg B, Glass PS, Fortney J, Jhaveri R, Perno R. Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate. Anesthesiology. 1997;87(5):1075\u201381.","journal-title":"Anesthesiology"},{"issue":"4","key":"912_CR11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1213\/01.ANE.0000148618.17736.3C","volume":"100","author":"LG Maxwell","year":"2005","unstructured":"Maxwell LG, Kaufmann SC, Bitzer S, Jackson EV, McGready J, Kost-Byerly S, et al. The effects of a small-dose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patient-controlled analgesia: a double-blind, prospective, randomized, controlled study. Anesth Analg. 2005;100(4):953\u20138.","journal-title":"Anesth Analg"},{"issue":"1\u20132","key":"912_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.pain.2003.09.011","volume":"107","author":"MS Cepeda","year":"2004","unstructured":"Cepeda MS, Alvarez H, Morales O, Carr DB. Addition of ultralow dose naloxone to postoperative morphine PCA: unchanged analgesia and opioid requirement but decreased incidence of opioid side effects. Pain. 2004;107(1\u20132):41\u20136.","journal-title":"Pain"},{"issue":"1","key":"912_CR13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/ANA.0000000000000374","volume":"30","author":"A Firouzian","year":"2018","unstructured":"Firouzian A, Gholipour Baradari A, Alipour A, Emami Zeydi A, Zamani Kiasari A, Emadi SA, et al. Ultra\u2013low-dose naloxone as an adjuvant to patient controlled analgesia (PCA) with morphine for postoperative pain relief following lumber discectomy: a double-blind, randomized, placebo-controlled trial. J Neurosurg Anesthesiol. 2018;30(1):26\u201331.","journal-title":"J Neurosurg Anesthesiol"},{"issue":"2\u20133","key":"912_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0304-3959(99)00223-7","volume":"84","author":"SM Crain","year":"2000","unstructured":"Crain SM, Shen KF. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance\/dependence liability. Pain. 2000;84(2\u20133):121\u201331.","journal-title":"Pain"},{"issue":"6","key":"912_CR15","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1213\/ANE.0b013e31822d39c1","volume":"113","author":"CP Yang","year":"2011","unstructured":"Yang CP, Cherng CH, Wu CT, Huang HY, Tao PL, Wong CS. Intrathecal ultra-low dose naloxone enhances the antinociceptive effect of morphine by enhancing the reuptake of excitatory amino acids from the synaptic cleft in the spinal cord of partial sciatic nerve\u2013transected rats. Anesth Analg. 2011;113(6):1490\u2013500.","journal-title":"Anesth Analg"},{"key":"912_CR16","unstructured":"Yao P, Meng L, Gui J. Effects of low-dose naloxone on morphine analgesia and plasma leveb of opiold peptldes. Chinese J Anesthesiol. 1996;07."},{"issue":"6","key":"912_CR17","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00432-018-2635-3","volume":"144","author":"ON Akta\u015f","year":"2018","unstructured":"Akta\u015f ON, \u00d6zt\u00fcrk AB, Erman B, Erus S, Tanju S, Dilege \u015e. Role of natural killer cells in lung cancer. J Cancer Res Clin Oncol. 2018;144(6):997\u20131003.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"912_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109976","volume":"9","author":"S Jin","year":"2014","unstructured":"Jin S, Deng Y, Hao JW, Li Y, Liu B, Yu Y, et al. NK cell phenotypic modulation in lung cancer environment. PLoS One. 2014;9(10):e109976.","journal-title":"PLoS One"},{"issue":"1","key":"912_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0169-5002(01)00292-6","volume":"35","author":"FR Villegas","year":"2002","unstructured":"Villegas FR, Coca S, Villarrubia VG, Jim\u00e9nez R, Chill\u00f3n MJ, Jare\u00f1o J, et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer. 2002;35(1):23\u20138.","journal-title":"Lung Cancer"},{"issue":"6013","key":"912_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.1198687","volume":"331","author":"E. Vivier","year":"2011","unstructured":"Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44\u20139.","journal-title":"Science"},{"issue":"7","key":"912_CR21","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.4049\/jimmunol.178.7.4011","volume":"178","author":"L Zamai","year":"2007","unstructured":"Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L, et al. NK cells and cancer. J Immunol. 2007;178(7):4011\u20136.","journal-title":"J Immunol"},{"issue":"5","key":"912_CR22","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/bjc.2014.384","volume":"111","author":"JW Boland","year":"2014","unstructured":"Boland JW, McWilliams K, Ahmedzai SH, Pockley AG. Effects of opioids on immunologic parameters that are relevant to anti-tumour immune potential in patients with cancer: a systematic literature review. Br J Cancer. 2014;111(5):866.","journal-title":"Br J Cancer"},{"issue":"3","key":"912_CR23","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jaci.2013.07.030","volume":"132","author":"G Deniz","year":"2013","unstructured":"Deniz G, van de Veen W, Akdis M. Natural killer cells in patients with allergic diseases. J Allergy Clin Immunol. 2013;132(3):527\u201335.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"912_CR24","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1007\/s12032-012-0176-1","volume":"29","author":"M Dehghani","year":"2012","unstructured":"Dehghani M, Sharifpour S, Amirghofran Z, Zare HR. Prognostic significance of T cell subsets in peripheral blood of B cell non-Hodgkin\u2019s lymphoma patients. Med Oncol. 2012;29(4):2364\u201371.","journal-title":"Med Oncol"},{"key":"912_CR25","doi-asserted-by":"crossref","unstructured":"Xu M, Bennett DL, Querol LA, Wu LJ, Irani SR, Watson JC, et al. Pain and the immune system: emerging concepts of IgG-mediated autoimmune pain and immunotherapies. J Neurol Neurosurg Psychiatry. 2018; jnnp-2018.","DOI":"10.1136\/jnnp-2018-318556"},{"issue":"9","key":"912_CR26","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1097\/EJA.0b013e32832c5280","volume":"26","author":"D Cardone","year":"2009","unstructured":"Cardone D, Klein AA. Perioperative blood conservation. Eur J Anaesthesiol. 2009;26(9):722\u20139.","journal-title":"Eur J Anaesthesiol"},{"issue":"1","key":"912_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1600-6143.2006.01591.x","volume":"7","author":"IQ Molenaar","year":"2007","unstructured":"Molenaar IQ, Warnaar N, Groen H, Tenvergert EM, Slooff MJH, Porte RJ. Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis. Am J Transplant. 2007;7(1):185\u201394.","journal-title":"Am J Transplant"},{"issue":"12","key":"912_CR28","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1097\/01.tp.0000250935.41034.2d","volume":"82","author":"M Ohira","year":"2006","unstructured":"Ohira M, Ohdan H, Mitsuta H, Ishiyama K, Tanaka Y, Igarashi Y, Asahara T. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy. Transplantation. 2006;82(12):1712\u20139.","journal-title":"Transplantation"},{"issue":"6","key":"912_CR29","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1213\/ANE.0b013e3181de0ab6","volume":"110","author":"A Gottschalk","year":"2010","unstructured":"Gottschalk A, Sharma S, Ford J, Durieux ME, Tiouririne M. The role of the perioperative period in recurrence after cancer surgery. Anesth Analg. 2010;110(6):1636\u201343.","journal-title":"Anesth Analg"},{"issue":"11","key":"912_CR30","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0006-2952(03)00085-6","volume":"65","author":"G Wei","year":"2003","unstructured":"Wei G, Moss J, Yuan CS. Opioid-induced immunosuppression: is it centrally mediated or peripherally mediated? Biochem Pharmacol. 2003;65(11):1761\u20136.","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"912_CR31","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1111\/j.1399-6576.2007.01448.x","volume":"51","author":"YL Ge","year":"2007","unstructured":"Ge YL, Lv R, Zhou W, Ma XX, Zhong TD, Duan ML. Brain damage following severe acute normovolemic hemodilution in combination with controlled hypotension in rats. Acta Anaesthesiol Scand. 2007;51(10):1331\u20137.","journal-title":"Acta Anaesthesiol Scand"},{"issue":"5","key":"912_CR32","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/phar.1930","volume":"37","author":"RW Barrons","year":"2017","unstructured":"Barrons RW, Woods JA. Low-dose naloxone for prophylaxis of postoperative nausea and vomiting: a systematic review and meta-analysis. Pharmacotherapy. 2017;37(5):546\u201354.","journal-title":"Pharmacotherapy"},{"issue":"7","key":"912_CR33","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1258\/ebm.2011.011096","volume":"236","author":"RN Donahue","year":"2011","unstructured":"Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Exp Biol Med. 2011;236(7):883\u201395.","journal-title":"Exp Biol Med"},{"issue":"6","key":"912_CR34","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1213\/ANE.0000000000000020","volume":"117","author":"CP Yang","year":"2013","unstructured":"Yang CP, Cherng CH, Wu CT, Huang HY, Tao PL, Lee SO, Wong CS. Intrathecal ultra-low dose naloxone enhances the antihyperalgesic effects of morphine and attenuates tumor necrosis factor-\u03b1 and tumor necrosis factor-\u03b1 receptor 1 expression in the dorsal horn of rats with partial sciatic nerve transection. Anesth Analg. 2013;117(6):1493\u2013502.","journal-title":"Anesth Analg"},{"issue":"2","key":"912_CR35","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ygyno.2011.04.009","volume":"122","author":"RN Donahue","year":"2011","unstructured":"Donahue RN, McLaughlin PJ, Zagon IS. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. Gynecol Oncol. 2011;122(2):382\u20138.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"912_CR36","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.bcp.2012.05.018","volume":"84","author":"PJ McLaughlin","year":"2012","unstructured":"McLaughlin PJ, Zagon IS. The opioid growth factor\u2013opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease. Biochem Pharmacol. 2012;84(6):746\u201355.","journal-title":"Biochem Pharmacol"}],"container-title":["BMC Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-019-0912-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12871-019-0912-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-019-0912-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T19:24:22Z","timestamp":1608233062000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcanesthesiol.biomedcentral.com\/articles\/10.1186\/s12871-019-0912-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["912"],"URL":"https:\/\/doi.org\/10.1186\/s12871-019-0912-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.14430\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.14430\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.14430\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.14430\/v4","asserted-by":"object"}]},"ISSN":["1471-2253"],"issn-type":[{"value":"1471-2253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"28 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This clinical trial was approved by Ethics Committee of the First Affiliated Hospital of the Dalian Medical University on January 24, 2019 (protocol number: PJ-KY-2018-141(X)). All the participants provided written informed consent following principles of the Helsinki Declaration.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"236"}}